Adicet Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACET Nasdaq 8731 https://www.adicetbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adicet Bio Inc

Adicet Bio to Present at Upcoming Investor Conferences - May 18th, 2022 8:00 pm
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit - May 15th, 2022 12:21 pm
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates - May 12th, 2022 8:10 pm
Further weakness as Adicet Bio (NASDAQ:ACET) drops 31% this week, taking one-year losses to 17% - May 12th, 2022 3:14 pm
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies - May 5th, 2022 11:00 am
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 4th, 2022 8:10 pm
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 27th, 2022 2:00 pm
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001 - Apr 19th, 2022 11:00 am
Adicet Bio to Participate in Upcoming Investor Conferences - Apr 7th, 2022 8:10 pm
The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider - Mar 22nd, 2022 4:47 pm
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress - Mar 15th, 2022 8:00 pm
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation - Mar 15th, 2022 11:25 am
Adicet Bio to Participate in Guggenheim 2022 Oncology Conference - Feb 2nd, 2022 12:00 pm
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Dec 10th, 2021 9:01 pm
How a biotech is turning 'road bikes' into 'mountain bikes' to roll over cancer - Dec 9th, 2021 10:49 pm
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock - Dec 8th, 2021 6:13 am
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock - Dec 7th, 2021 9:16 pm
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy - Dec 6th, 2021 12:00 pm
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma - Nov 29th, 2021 12:00 pm
Adicet Bio (NASDAQ:ACET) shareholders have endured a 27% loss from investing in the stock a year ago - Nov 20th, 2021 11:00 am